Nature Search

Tissue Microarray Profiling of Cancer Specimens and Cell Lines: Opportunities and Limitations

Axel Hoos
Carlos Cordon-Cardo
Reviews01 Oct 2001
Laboratory Investigation

Volume: 81, P: 1331-1338
Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations

Immuno-oncology has become the fastest-growing area in the pharmaceutical industry. In this Perspective, Hoos provides an overview of the history of immuno-oncology and investigates the factors that have led to its success. Moreover, he discusses the three generations of immunotherapies that have been developed since 2011 and provides an outlook to the future directions of drug discovery and development in immuno-oncology.

Axel Hoos
Reviews11 Mar 2016
Nature Reviews Drug Discovery

Volume: 15, P: 235-247
CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS

The prognosis for patients with advanced melanoma and CNS metastases is poor. Hodi et al. report the case of a 63-year-old female who was diagnosed with metastatic melanoma from an unknown primary tumor. The authors discuss the use of the human monoclonal antibody against CTLA-4, ipilimumab, in patients with metastatic melanoma.

F Stephen Hodi
Darryl A Oble
Martin Mihm
Reviews29 Jul 2008
Nature Clinical Practice Oncology

Volume: 5, P: 557-561
Author Correction: Design of amidobenzimidazole STING receptor agonists with systemic activity

Joshi M. Ramanjulu
G. Scott Pesiridis
John Bertin
Amendments and Corrections30 May 2019
Nature

Volume: 570, P: E53
Big opportunities for small molecules in immuno-oncology

Small-molecule drugs have several advantages that are complementary to, and possibly synergistic with, biologic approaches for anticancer immunotherapy. This Review provides an overview of immunological pathways that can best be targeted with small molecules and discusses how these approaches fit into the armamentarium of immunotherapeutic strategies for cancer.

Jerry L. Adams
James Smothers
Axel Hoos
Reviews31 Jul 2015
Nature Reviews Drug Discovery

Volume: 14, P: 603-622
A methodological framework to enhance the clinical success of cancer immunotherapy

Axel Hoos
Cedrik M Britten
Jill O'Donnell-Tormey
Correspondence13 Oct 2011
Nature Biotechnology

Volume: 29, P: 867-870
Design of amidobenzimidazole STING receptor agonists with systemic activity

A small-molecule agonist for the cGAS–STING pathway has systemic activity in a mouse model of colon cancer.

Joshi M. Ramanjulu
G. Scott Pesiridis
John Bertin
Research07 Nov 2018
Nature

Volume: 564, P: 439-443
How GlaxoSmithKline is advancing efficient drug development in haematologic malignancies

Axel Hoos
Ira Gupta
Special Features25 Nov 2020
Nature Research Custom
The promise and challenges of immune agonist antibody development in cancer

Co-stimulatory receptors mediate the anticancer immune response. This Review discusses the current efforts in targeting co-stimulatory receptors with agonist antibodies and the landscape of agonist antibodies in clinical development for cancer treatment.

Patrick A. Mayes
Kenneth W. Hance
Axel Hoos
Reviews15 Jun 2018
Nature Reviews Drug Discovery

Volume: 17, P: 509-527
Industrializing engineered autologous T cells as medicines for solid tumours

Despite the rapid growth of the engineered cell therapy sector, there are challenges to the broader industrialization of cells as medicines, especially in the treatment of solid tumours. This Perspective provides an industry perspective on the progress achieved by engineered T cell therapies and discusses strategies to industrialize their potential.

Cedrik M. Britten
Aiman Shalabi
Axel Hoos
Reviews08 Apr 2021
Nature Reviews Drug Discovery

Volume: 20, P: 476-488
The regulatory landscape for actively personalized cancer immunotherapies

Cedrik M Britten
Harpreet Singh-Jasuja
Ulrich Kalinke
Correspondence08 Oct 2013
Nature Biotechnology

Volume: 31, P: 880-882
Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

Suzanne Trudel
Nikoletta Lendvai
Adam D. Cohen
ResearchOpen Access20 Mar 2019
Blood Cancer Journal

Volume: 9, P: 1-10
Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study

Paul G. Richardson
Hans C. Lee
Sagar Lonial
ResearchOpen Access23 Oct 2020
Blood Cancer Journal

Volume: 10, P: 1-11
Guidelines for the automated evaluation of Elispot assays

This protocol summarizes the recommendations developed after a comparison of Elispot plate-reading approaches by a panel of laboratories and subsequent agreement regarding the optimal steps to follow when evaluating Elispot plates.

Sylvia Janetzki
Leah Price
Axel Hoos
Protocols25 Jun 2015
Nature Protocols

Volume: 10, P: 1098-1115
Adrenocortical Adenoma and Carcinoma: Histopathological and Molecular Comparative Analysis

Alexander Stojadinovic
Murray F Brennan
Ronald A Ghossein
Research01 Aug 2003
Modern Pathology

Volume: 16, P: 742-751

Search

Filter By:

Search

Quick links